Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Artificial Intelligence in MASLD: A Three-Level Framework Across Clinical, Health-System, and Policy Decisions.
Clinical takeawayNo clinical action yet: AI applications in MASLD are promising but remain unvalidated in prospective multicenter studies and lack evidence of improved clinical outcomes.
What it foundAI models perform comparably to or better than conventional non-invasive tests (e.g., FIB-4, VCTE) and expert interpretation in fibrosis assessment, histopathologic and imaging interpretation, multi-omics integration, and hepatocellular carcinoma risk stratification, but no validated tool predicts treatment response before therapy. Current evidence is largely retrospective, single-center, and lacks external validation.
ContextThis review highlights the potential of AI in MASLD care but underscores the need for robust validation, implementation frameworks, and governance, as current evidence is largely retrospective and single-center.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Kalligeros M … Younossi ZM · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗